Minghui Li; Qi Wang; Weihua Cao; Yao Xie; Minghui Li; Qi Wang; Weihua Cao; Yao Xie

doi:10.46234/ccdcw2025.263

[1]

Asselah T, Rizzetto M. Hepatitis D virus infection. N Engl J Med 2023;389(1):58 − 70. https://doi.org/10.1056/NEJMra2212151.

[2]

Stockdale AJ, Kreuels B, Henrion MYR, Giorgi E, Kyomuhangi I, de Martel C, et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J Hepatol 2020;73(3):523 − 32. https://doi.org/10.1016/j.jhep.2020.04.008.

[3]

Njuguna HN, Hiebert L, Harris A, Morgan RL, Gupta N, Ward JW. An assessment of national strategic action plans for viral hepatitis elimination, 2016-2021. J Infect Dis 2023;228(Suppl 3):S148 − 53. https://doi.org/10.1093/infdis/jiad346.

[4]

Blaney H, Khalid M, Heller T, Koh C. Epidemiology, presentation, and therapeutic approaches for hepatitis D infections. Expert Rev Anti Infect Ther 2023;21(2):127 − 42. https://doi.org/10.1080/14787210.2023.2159379.

[5]

Miao Z, Zhang S, Ou X, Li S, Ma Z, Wang W, et al. Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection. J Infect Dis. 2020;221(10):1677 − 1687 https://doi.org/10.1093/infdis/jiz633.

[6]

Hayashi T, Takeshita Y, Hutin YJF, Harmanci H, Easterbrook P, Hess S, et al. The global hepatitis delta virus (HDV) epidemic: what gaps to address in order to mount a public health response? Arch Public Health 2021;79(1):180. http://dx.doi.org/10.1186/s13690-021-00693-2.

[7]

Illescas-López M, Chaves-Blanco L, de Salazar A, Hernández-Febles M, Carracedo R, Lagarejos E, et al. Assessment of performance and comparison of three commercial HDV RNA detection assays: implications for diagnosis and treatment monitoring. Front Cell Infect Microbiol 2024;14:1422299. https://doi.org/10.3389/fcimb.2024.1422299.

[8]

Akuffo GA, Ouoba S, Ko K, Chhoung C, Phyo Z, Mirzaev UK, et al. Assessing the diagnostic accuracy of serological tests for hepatitis delta virus diagnosis: a systematic review and meta-analysis. Sci Rep 2024;14(1):18475. https://doi.org/10.1038/s41598-024-69304-8.

[9]

Negro F, Lok AS. Hepatitis D: a review. JAMA 2023;330(24):2376 − 87. https://doi.org/10.1001/jama.2023.23242.

[10]

Wedemeyer H, Aleman S, Brunetto MR, Blank A, Andreone P, Bogomolov P, et al. A phase 3, randomized trial of bulevirtide in chronic hepatitis D. N Engl J Med 2023;389(1):22 − 32. https://doi.org/10.1056/NEJMoa2213429.

[11]

Yang Q, Xue B, Liu FJ, Lu YZ, Tang JL, Yan MR, et al. Farnesyltransferase inhibitor lonafarnib suppresses respiratory syncytial virus infection by blocking conformational change of fusion glycoprotein. Signal Transduct Target Ther 2024;9(1):144. https://doi.org/10.1038/s41392-024-01858-5.

[12]

Buti M, Gonzalez A, Riveiro-Barciela M, Bourliere M. Management of chronic HBV-HDV patients chronic HBV-HDV infection: a review on new management options. United Eur Gastroenterol J 2024;12(2):210 − 8. https://doi.org/10.1002/ueg2.12494.

[13]

Zhou JY, Kaiser H, Rocha E, Terrell AN, Corti D, Purcell LA, et al. Therapy with murinized tobevibart and elebsiran is efficacious in a liver-chimeric mouse model of HDV infection. JHEP Reports 2025;7(6):101400. https://doi.org/10.1016/j.jhepr.2025.101400.

[14]

Wang XR, Chi XM, Zhang YY, Gu YM, Xiao L, Qi YH, et al. Safety and efficacy of anti-pre-S1 domain monoclonal antibody (HH-003) treatment in patients with co-infection of chronic hepatitis B virus (HBV) and hepatitis D virus (HDV): a single center, open-label, phase 2 trial. J Hepatol 2023;78(Suppl S1):S117. https://doi.org/10.1016/S0168-8278(23)00606-2.

[15]

Buti M, Spearman CW, Siebelt K, El-Sayed M. Hepatitis D epidemiology and access to diagnostic testing among healthcare providers in Africa: a multi-country survey. JHEP Rep 2025;7(9):101495. https://doi.org/10.1016/j.jhepr.2025.101495.

[16]

World Health Organization. Global Health Sector Strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030. Geneva: WHO; 2022. https://www.who.int/publications/i/item/9789240053779.

[17]

Cooke GS, Flower B, Cunningham E, Marshall AD, Lazarus JV, Palayew A, et al. Progress towards elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission update. Lancet Gastroenterol Hepatol 2024;9(4):346 − 65. https://doi.org/10.1016/s2468-1253(23)00321-7.

[18]

Bai XX, Chen L, Liu XY, Tong YJ, Wang L, Zhou MR, et al. Adult hepatitis B virus vaccination coverage in China from 2011 to 2021: a systematic review. Vaccines 2022;10(6):900. https://doi.org/10.3390/vaccines10060900.

[19]

Matthews PC, Ocama P, Wang S, El-Sayed M, Turkova A, Ford D, et al. Enhancing interventions for prevention of mother-to-child- transmission of hepatitis B virus. JHEP Rep 2023;5(8):100777. https://doi.org/10.1016/j.jhepr.2023.100777.

[20]

Ghany MG, Buti M, Lampertico P, Lee HM, 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference Faculty. Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference. Hepatology 2023;78(5):1654 − 73. https://doi.org/10.1097/hep.0000000000000431.